Melt Extrusion: Shaping Drug Delivery in the 21st Century - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Melt Extrusion: Shaping Drug Delivery in the 21st Century
The authors provde a review of melt extrusion's evolution and applications in the pharmaceutical industry. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s30-s37

This article is part of a special issue on Drug Delivery

Melt extrusion has been an established industrial manufacturing technology for more than 50 years and has been applied to the production of everything from layered trash bags and space-shuttle parts to synthetic wine corks. During the past decade, the technology has emerged as a viable platform for pharmaceutical development. Today, melt-extrusion applications for pharmaceutical production range from controlled-release systems to oral bioavailability enhancement and show potential for small molecules and therapeutic peptides.

Pioneering development activities in the late 1980s and 1990s spawned several amorphous compositions, including Sporanox (Janssen Pharmaceuticals, Titusville, NJ), Prograf (Astellas Pharma, Deerfield, NJ), and Rezulin (Parke-Davis*), leading to the general acceptance of solid dispersions (1–3). Driven by the continuing development of new chemical entities with limited solubility and industrial aims at continuous commercial manufacturing, melt extrusion has gained acceptance for improving bioavailability and increasing manufacturing efficiencies (4, 5). The emergence of novel drug-delivery systems and routes of administration also have allowed for the expansion of melt-extrusion applications within the pharmaceutical industry. This review article presents an overview of the processing technology, covering four major areas of application: bioavailability enhancement, oral controlled release, melt granulation, and the production of advanced controlled-release dosage forms.

Twin-screw extrusion

Twin-screw extruders (TSEs) process materials in channels bounded by screw flights and barrel walls, and are therefore referred to as small-mass continuous mixers. The motor inputs energy into the process through rotating screws. Process-control parameters include screw speed (rpm), feed rate, temperatures along the barrel and die, and vacuum level (6). Typical monitoring parameters for in-line quality measurement include melt pressure, melt temperature, motor amperage, and near-infrared (NIR) sensors.


Table I: Oral bioavailability of itraconazole solid-dispersion formulations in healthy volunteers (n = 8). Adapted from Six et al. (Ref. 14).
TSEs use segmented screws that are assembled on high torque shafts. Barrels are modular and integrate internal bores for cooling. Segmented screws/barrels, in combination with the controlled pumping and wiping characteristics of corotating, self-wiping screws, allow screw and barrel geometries to be matched to the process tasks (6, 7). The counter-rotating intermeshing twin screw mode is also used in the pharmaceutical industry. Solids convey and melt during the first part of the process section. Screw elements for mixing and devolatilization are used as dictated by the process. Discharge elements help to build and stabilize pressure (see Figure 1).

TSEs are starve-fed, with the output rate determined by the feeder(s), which can meter pellets, liquids, powders, and fibers into the process section (8). The TSE screw speed is independent from the feed rate and used to optimize compounding efficiencies. Because the pressure gradient in the extruder process section is zero for much of the process, materials can be introduced into downstream barrel sections to facilitate sequential feeding (7). For instance, a shear-sensitive active pharmaceutical ingredient (API) can be metered in the latter stages of the process section.

TSE processing offers advantages over batch manufacturing techniques. Polymers are specified to function as thermal binders and act as drug depots and drug-release retardants upon cooling and solidification. Solvents and water are generally not necessary for processing, which reduces process steps. Expensive drying equipment is eliminated as well, along with time-consuming drying steps.

The intense mixing associated with the short interscrew mass-transfer characteristics inherent in a TSE small-mass continuous mixer results in highly efficient distributive and dispersive mixing that leads to a more uniform product compared with large mass-batch mixers (7). Entrapped air, moisture, and volatiles are also removed by vacuum venting during the extrusion process. The short residence time associated with a TSE process compared with a batch process is beneficial for many heat and shear-sensitive materials because the TSE can be designed to limit exposure to elevated temperatures to a few seconds.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here